These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 31323137)
41. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Navarro RP; Morrow T; Baran R Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298 [TBL] [Abstract][Full Text] [Related]
42. It is not only the empty vials that go into the garbage can during chemotherapy drugs preparation: a cost analysis of unused chemotherapy drugs in cancer treatment. Ata A; Abali H; Yengel E; Arican A J BUON; 2012; 17(4):781-4. PubMed ID: 23335541 [TBL] [Abstract][Full Text] [Related]
43. The budget impact of controlling wastage with smaller vials: A data driven model of session sizes in Bangladesh, India (Uttar Pradesh),Mozambique, and Uganda. Yang W; Parisi M; Lahue BJ; Uddin M; Bishai D Vaccine; 2014 Nov; 32(49):6643-8. PubMed ID: 25306911 [TBL] [Abstract][Full Text] [Related]
44. Physical wastage of immunobiological products in the state of Ceará, Brazil, 2014-2016. Seabra Filho FT; Moura ADA; Braga AVL; Jereissati NCC; Câncio KS; Silva MGCD Epidemiol Serv Saude; 2020; 29(2):e2019004. PubMed ID: 32401882 [TBL] [Abstract][Full Text] [Related]
45. Opportunities to significantly reduce expenditure associated with cancer drugs. Gilbar PJ; Chambers CR; Gilbar EC Future Oncol; 2017 Jun; 13(15):1311-1322. PubMed ID: 28589775 [TBL] [Abstract][Full Text] [Related]
46. Minimalism in oncology. The Lancet Oncology Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372 [No Abstract] [Full Text] [Related]
47. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303 [TBL] [Abstract][Full Text] [Related]
48. Do oncologists believe new cancer drugs offer good value? Nadler E; Eckert B; Neumann PJ Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830 [TBL] [Abstract][Full Text] [Related]
49. The Cost of Enfortumab Vedotin Wastage Due to Vial Size-A Real-World Analysis. Sarfaty M; Moore A; Regazzi AM; Mitchell AP; Rosenberg JE Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885086 [TBL] [Abstract][Full Text] [Related]
50. Vaccine Wastage Assessment After Introduction of Open Vial Policy in Surat Municipal Corporation Area of India. Patel PB; Rana JJ; Jangid SG; Bavarva NR; Patel MJ; Bansal RK Int J Health Policy Manag; 2015 Dec; 5(4):233-6. PubMed ID: 27239864 [TBL] [Abstract][Full Text] [Related]
51. Potential cost savings associated with dose rounding antineoplastic monoclonal agents. Francis SM; Heyliger A; Miyares MA; Viera M J Oncol Pharm Pract; 2015 Aug; 21(4):280-4. PubMed ID: 24821690 [TBL] [Abstract][Full Text] [Related]
52. Oncology drug costs-the imaginary crisis? Turck R Ann Oncol; 2017 Feb; 28(2):427-431. PubMed ID: 27771612 [No Abstract] [Full Text] [Related]
53. Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France. Hurtaud A; Donnadieu A; Escalup L; Cottu PH; Baffert S Breast; 2016 Dec; 30():73-79. PubMed ID: 27639032 [TBL] [Abstract][Full Text] [Related]
54. Drug assistance programs for the cancer patient. Mowad LZ; Richter SS Cancer Pract; 2000; 8(1):49-50. PubMed ID: 10732540 [No Abstract] [Full Text] [Related]
56. Anesthetic drug wastage in the operation room: A cause for concern. Chaudhary K; Garg R; Bhalotra AR; Anand R; Girdhar K J Anaesthesiol Clin Pharmacol; 2012 Jan; 28(1):56-61. PubMed ID: 22345947 [TBL] [Abstract][Full Text] [Related]
57. A Cost Saving and Waste Minimization Study About Handling of the Antineoplastic Agents. Karakoç MD Turk J Pharm Sci; 2017 Dec; 14(3):304-310. PubMed ID: 32454629 [TBL] [Abstract][Full Text] [Related]
58. Estimated Cost and Savings in a Patient Management Program for Oral Oncology Medications: Impact of a Split-Fill Component. Staskon FC; Kirkham HS; Pfeifer A; Miller RT J Oncol Pract; 2019 Oct; 15(10):e856-e862. PubMed ID: 31465250 [TBL] [Abstract][Full Text] [Related]
59. Cost drivers for breast, lung, and colorectal cancer care in a commercially insured population over a 6-month episode: an economic analysis from a health plan perspective. Sagar B; Lin YS; Castel LD J Med Econ; 2017 Oct; 20(10):1018-1023. PubMed ID: 28581874 [TBL] [Abstract][Full Text] [Related]
60. [Costs of cancer chemotherapy]. Kjaer M Ugeskr Laeger; 1994 Jan; 156(4):449-50. PubMed ID: 8140659 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]